Research programme: selective estrogen receptor modulators - Ligand/Pfizer

Drug Profile

Research programme: selective estrogen receptor modulators - Ligand/Pfizer

Alternative Names: Research programme: SERMs - Ligand/Pfizer; Selective estrogen receptor modulators - Abbot/Pfizer; SERMs research programme - Ligand/Pfizer

Latest Information Update: 07 Feb 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ligand Pharmaceuticals; Pfizer
  • Class Small molecules
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease; Breast cancer; Menopausal syndrome; Postmenopausal osteoporosis

Most Recent Events

  • 07 Feb 2001 Discontinued-Preclinical for Alzheimer's disease in USA (Unknown route)
  • 07 Feb 2001 Discontinued-Preclinical for Breast cancer prevention in USA (Unknown route)
  • 07 Feb 2001 Discontinued-Preclinical for Breast cancer treatment in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top